In our retrospective analysis of 21 patients with the ABC subtype of DLBCL, 33% of patients treated with R-CHOP either progressed or relapsed, whereas none of the patients treated with DA-REPOCH progressed or relapsed (p = 0.1038). Additionally, lymphoma or its treatment was responsible for death of 25% of patients treated with R-CHOP compared to only 11% of those treated with DA-REPOCH. Here, DDIT3 is linked to diffuse large B-cell lymphoma.